Australian life science companies presented to local life science investors in Asia earlier this month, as part of AusBiotech’s high-profile investment series.
The Asian investment series attracted over 200 investors and 30 life science companies and signified a valuable opportunity to strengthen connections between companies and the investment community.
Held in Hong Kong and Singapore, the third and fourth largest financial centres in the world respectively, these events benefitted from a growing interest in the life sciences and placed emphasis on Australian opportunities, digital health and medical devices.
In Hong Kong, investors demonstrated a growing interest in pre-IPO companies.
“There is a history of Hong Kong-based institutional investors investing in Australian listed companies. This interest has now extended to private and earlier stage companies. There is particular interest in companies that have products with competitive advantage or relevance to the Chinese market,” says AusBiotech Chief Operations Officer, Glenn Cross.
Delegates in Hong Kong also benefitted from the BioInvest Partnering System, which helped schedule more than 100 meetings between investors and life companies.
The event in Singapore was held in partnership with the Singapore Exchange (SGX).
“There is capital available and people are looking for investment opportunities, but there are limited opportunities from local Singaporean R&D activities. Australia is recognised as a producer of great science and our close proximity to Singapore, in addition to common time zones, gives these companies a strong advantage,” says Mr Cross.